News

31 August 2023

Two posters, highlighting HaemaLogiX results, will be presented at International Myeloma Society, Athens

Image-empty-state_edited_edited_edited.j

31 August 2023

14 August 2023

HaemaLogiX's CSO, Dr Rosanne Dunn, to speak at Cell and Gene Therapy World Asia, Singapore

14 August 2023

25 July 2023

HaemaLogiX to take KMA.CAR-T to Ph1 trial with Peter Mac

25 July 2023

28 June 2023

Positive final KappaMab Ph2b study results announced

28 June 2023

19 June 2023

June 2023 newsletter

19 June 2023

15 June 2023

HaemaLogiX abstract accepted for publication at the International Conference on Malignant Lymphoma

15 June 2023

14 June 2023

Watch: Inside the KappaMab manufacturing process

14 June 2023

30 May 2023

Watch: Karen Wilde, myeloma patient story

30 May 2023

23 May 2023

Watch: Our value inflection points between Q2 2023 and FY 2024

23 May 2023

16 May 2023

Watch: The competitive advantage of our immunotherapies explained

16 May 2023

9 May 2023

Watch: Meet our team: Dr Geoffrey Nichol

9 May 2023

2 May 2023

Watch: For investors, interview series with Dr Geoffrey Nichol

2 May 2023

27 April 2023

Poster presentation at 2023 AACR meeting

27 April 2023

3 April 2023

HaemaLogiX announces issuance of Japanese patent for KMA.CAR T

3 April 2023

21 December 2022

Watch: The latest on our CAR-T technology at Myeloma Australia’s 4th Workshop

21 December 2022

20 December 2022

Watch: Our CSO Dr Rosanne Dunn presenting on our novel antigens LMA and KMA at ASH 2022

20 December 2022

15 December 2022

Watch: What makes our immunotherapies different on the growing myeloma treatment market

15 December 2022

17 October 2022

AusBiotech 2022: HaemaLogiX CEO Bryce Carmine to present

17 October 2022

12 October 2022

Watch: Everything you need to know about HaemaLogiX right now, CEO interview

12 October 2022

11 October 2022

HaemaLogiX’s CAR-Ts to feature at 4th National Myeloma Workshop

11 October 2022

27 September 2022

HaemaLogiX announces issuance of US patent for LMA

27 September 2022

15 August 2022

Watch: Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process

15 August 2022

7 July 2022

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

7 July 2022

7 July 2022

HaemaLogiX announces issuance of USA patent for KMA.CAR T

7 July 2022

27 January 2022

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

27 January 2022

17 January 2022

HaemaLogiX welcomes Tertia Dex to the team

17 January 2022

21 December 2021

HaemaLogiX welcomes Professor Simon Harrison to the SAB

21 December 2021

15 December 2021

Full presentation materials on the novel antigens LMA and KMA at the 63rd annual ASH meeting are now available

15 December 2021

5 November 2021

Dr Mary Sartor to present research on LMA and the 10B3 monoclonal antibody developed by HaemaLogiX at ASH 2021

5 November 2021

12 September 2021

Platinum leads immuno-oncology company HaemaLogiX’s $10m capital-raising round

12 September 2021

8 September 2021

HaemaLogiX raises $10 million to advance multiple myeloma treatments

8 September 2021

5 February 2021

HaemaLogiX announces collaboration with the Peter MacCallum Cancer Centre

5 February 2021

29 January 2021

Orphan Drug Designation for KappaMab transferred to HaemaLogiX

29 January 2021

22 January 2021

HaemaLogiX announces issuance of Australian patent for LMA

22 January 2021

16 October 2020

HaemaLogiX Announces the Outcomes of Two Innovation Connections Grant Projects

16 October 2020

9 October 2020

Bryce Carmine to present at AusBiotech & Invest 2020

9 October 2020

News & Events

31 August 2023

Two posters, highlighting HaemaLogiX results, will be presented at International Myeloma Society, Athens

14 August 2023

HaemaLogiX's CSO, Dr Rosanne Dunn, to speak at Cell and Gene Therapy World Asia, Singapore

25 July 2023

HaemaLogiX to take KMA.CAR-T to Ph1 trial with Peter Mac

28 June 2023

Positive final KappaMab Ph2b study results announced

19 June 2023

June 2023 newsletter

15 June 2023

HaemaLogiX abstract accepted for publication at the International Conference on Malignant Lymphoma

14 June 2023

Watch: Inside the KappaMab manufacturing process

30 May 2023

Watch: Karen Wilde, myeloma patient story

23 May 2023

Watch: Our value inflection points between Q2 2023 and FY 2024

16 May 2023

Watch: The competitive advantage of our immunotherapies explained

9 May 2023

Watch: Meet our team: Dr Geoffrey Nichol

2 May 2023

Watch: For investors, interview series with Dr Geoffrey Nichol

27 April 2023

Poster presentation at 2023 AACR meeting

3 April 2023

HaemaLogiX announces issuance of Japanese patent for KMA.CAR T

21 December 2022

Watch: The latest on our CAR-T technology at Myeloma Australia’s 4th Workshop

20 December 2022

Watch: Our CSO Dr Rosanne Dunn presenting on our novel antigens LMA and KMA at ASH 2022

15 December 2022

Watch: What makes our immunotherapies different on the growing myeloma treatment market

17 October 2022

AusBiotech 2022: HaemaLogiX CEO Bryce Carmine to present

12 October 2022

Watch: Everything you need to know about HaemaLogiX right now, CEO interview

11 October 2022

HaemaLogiX’s CAR-Ts to feature at 4th National Myeloma Workshop

27 September 2022

HaemaLogiX announces issuance of US patent for LMA

15 August 2022

Watch: Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process

7 July 2022

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

7 July 2022

HaemaLogiX announces issuance of USA patent for KMA.CAR T

27 January 2022

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

17 January 2022

HaemaLogiX welcomes Tertia Dex to the team

21 December 2021

HaemaLogiX welcomes Professor Simon Harrison to the SAB

15 December 2021

Full presentation materials on the novel antigens LMA and KMA at the 63rd annual ASH meeting are now available

5 November 2021

Dr Mary Sartor to present research on LMA and the 10B3 monoclonal antibody developed by HaemaLogiX at ASH 2021

12 September 2021

Platinum leads immuno-oncology company HaemaLogiX’s $10m capital-raising round

8 September 2021

HaemaLogiX raises $10 million to advance multiple myeloma treatments

5 February 2021

HaemaLogiX announces collaboration with the Peter MacCallum Cancer Centre

29 January 2021

Orphan Drug Designation for KappaMab transferred to HaemaLogiX

22 January 2021

HaemaLogiX announces issuance of Australian patent for LMA

16 October 2020

HaemaLogiX Announces the Outcomes of Two Innovation Connections Grant Projects

9 October 2020

Bryce Carmine to present at AusBiotech & Invest 2020